ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
Research To Practice | Oncology Videos · Dr. Neil Love
November 5, 202541m 17s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Prof Patrick Neven, including the following topics:
- Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
- Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
- Emerging data with novel oral SERD combinations (6:31)
- Challenges for a general medical oncologist in breast cancer (8:41)
- Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)
- Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)